(AOF) – Pfizer is expected to fall 1.80% in pre-market on Wall Street; the Wall Street Journal stating that the American pharmaceutical giant would be in negotiations to buy the biotech Seagen, specialist in the treatment of cancer, for more than 30 billion dollars. The target, listed on Nasdaq, is for its part expected to rise by 15.88%. The journalist recalls the failure of the discussions initiated last year by Seagen with the Merck group, which proposed 40 billion dollars.